


A Novel RNA Lipid Nanoparticle Platform: Gene-Edited CAR T Cells for Off-the-Shelf Cancer Therapy

*Samuel Clarke, PhD
Director of Product Development*

July 14, 2022



Next Generation Immune Cell Therapies




Today

- High response in some advanced blood cancers
- Moderate toxicities
- Limited efficacy in solid tumors
- On-demand manufacturing
 - Autologous
 - Viral Vectors


Tomorrow

- Additional cancers and earlier lines of therapy
- Reduced toxicities
- Extension to solid tumors
- Off-the-shelf manufacturing
 - **Allogeneic**
 - **Gene-Edited**
 - **Non-Viral Delivery**


Lipid Nanoparticles for Genetic Engineering of T Cells



T Cell Kit Composition was Selected for Superior Performance in Primary T Cells




We have a **novel lipid library** comprising ionizable lipids and compositions that are **designed** for applications in **vaccines, gene therapy, and cell therapy**.



Methods: All component mole ratios maintained with only the ionizable lipid varied. GFP intensity and transfection efficiency was measured via flow cytometry 48 h post treatment. LNP treatment was performed following the T Cell Kit for mRNA on Spark protocol.


Proof-of-Concept Demonstration of *Ex Vivo* T Cell Engineering

1 Gene Expression




2nd generation CD19 CAR expression

2 Gene Knockout



TCR and/or CD52 double knockout


3 Gene Knockout and Expression




TCR knockout and subsequent CAR expression

1


LNPs Show High Transfection Efficiency and High Cell Viability





Transfection Efficiency



Protein Expression



Viability




Primary T cell


2

Gene Knockout: Dose-dependent Knockout Efficiency with High Cell Viabilities


A




B



C






D




Multi-step Engineering using LNPs: Knockout and Expression



TCR Knock Out





CAR Expression



In Vitro Killing Assay



For All (and More) Data, Please See Our New App Note!



Genome Editing of Human Primary T Cells with Lipid Nanoparticles

Gene edited CAR T cells for next-generation cell therapies

Authors: Reka Geczy, PhD, Aruna Balaji, Stella Park, Rita Zhao, Ethan Watt, Maggie Wong, Cooper Webb, Nikita Jain, PhD, Angela Zhang, PhD, Anitha Thomas, PhD, Samuel Clarke, PhD

Document ID: CRISPR-AN-0322

Precision NanoSystems ULC, Vancouver, BC, Canada



SparkTM




IgniteTM



BlazeTM



GMP



GenVoy[®] Reagents

Biopharmaceutical Services

Screening

Formulation
Development

Process
Development

Scale-up

Technology Transfer & Manufacturing

Chemistry, Manufacturing & Controls (CMC)
Support

Acknowledgements



PNI Reagents & Delivery Teams

- Reka Geczy
- Aruna Balgi
- Stella Park
- Rita Zhao
- Anitha Thomas
- Nikita Jain
- Angela Zhang

Funding

- Government of Canada IRAP-NRC Program

PNI Departments:

- Clinical Manufacturing
- Research
- Engineering & Operations
- Preclinical
- Process Development
- Product Development
- Analytical Development
- Quality Control
- Quality Assurance
- Project Management
- RNA Development Services
- Sales and Marketing

 [linkedin.com/company/precision-nanosystems-inc-](https://www.linkedin.com/company/precision-nanosystems-inc-)

 twitter.com/precisionnano

 youtube.com/PrecisionNanoSystems

Thank you for listening!

Questions?

